Crystagen 20mg
Synthetic tripeptide bioregulator (Glu-Asp-Pro) studied in Khavinson models for immune system modulation and cellular gene expression.
Mechanism
Hypothesized to penetrate cellular structures to modulate gene expression and transcription factors governing thymic and immune cell function.
Dosing
Standard laboratory protocols document an initial administration level of 1,000 mcg once daily, titrating up to 2,000 mcg daily.
Reconstitution
Adding 3.0 mL of bacteriostatic water to a 20 mg vial yields an operational concentration of approximately 6.67 mg/mL (6,667 mcg/mL).
Storage
Store the lyophilized vial at -20 °C protected from light, and keep the reconstituted liquid refrigerated between 2 °C and 8 °C for up to 28 days without freezing.
Mix & measure Crystagen 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Crystagen 20mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 20.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Week 1 | 1,000 mcg (1× daily) | ~15 units (0.15 mL) |
| Week 2 | 1,500 mcg (1× daily) | ~22.5 units (0.225 mL) |
| Weeks 3–12 | 2,000 mcg (1× daily) | ~30 units (0.30 mL) |
Reconstitution Steps
- 1
Sanitize the rubber stoppers of both the bacteriostatic water and the Crystagen vial using separate sterile alcohol pads.
- 2
Draw 3.0 mL of bacteriostatic water using an appropriately sized sterile syringe.
- 3
Insert the syringe needle into the Crystagen vial and slowly run the diluent down the inside glass wall to prevent excessive foaming.
- 4
Gently swirl and roll the vial between your palms until the lyophilized powder is completely dissolved, avoiding vigorous shaking.
- 5
Record the date, time, and concentration on the vial label and place it immediately into refrigerated storage at 2–8 °C.
Supplies Needed
Peptide Vial
Lyophilized Crystagen 20 mg vial providing the active research compound.
Insulin Syringes (U-100)
Precision U-100 syringes used to accurately draw micro-volumes for experimental administration.
Bacteriostatic Water
Sterile diluent preserved with 0.9% benzyl alcohol used to dissolve the peptide cake.
Alcohol Swabs
70% isopropyl alcohol prep pads used to maintain aseptic technique across vial septums and surfaces.
Why researchers study it
Immune modulation via targeted short-peptide signaling
Preclinical pathways in inflammatory regulation
Immunosenescence and age-associated immune cell decline
Epigenetic mechanisms and cellular gene expression
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Crystagen is a synthetic short-chain peptide bioregulator consisting of the tripeptide sequence glutamic acid, aspartic acid, and proline (Glu-Asp-Pro or EDP). Formulated as the targeted cytogen analog to bioactive compounds historically isolated from bovine thymus extract (Thymalin), it belongs to the Khavinson class of regulatory peptides. In preclinical research models, short bioregulatory peptides are evaluated for their potential to interact directly with nucleosomal DNA and histones to influence epigenetic transcription without hormonal receptor activation. Investigational studies primarily center around immune signaling pathways, immunosenescence, and cellular resilience during physiological stress. Because Crystagen remains an investigational research agent without therapeutic approval by regulatory authorities, laboratory handling requires precise sterile preparation, controlled reconstitution, and adherence to established reference dilutions to ensure accurate analytical results.
References
- 1.Khavinson et al., Biogerontology, 2002 — Structural characterization and gene-regulatory properties of Khavinson short peptide bioregulators
- 2.Khavinson et al., Cell Cycle, 2014 — Epigenetic mechanisms and transcription factor binding of synthetic tripeptides
- 3.Morozov et al., Russian State Pharmacological Annals, 1996 — Preclinical and clinical characterization of thymic peptide complexes
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allMOTS-c 10mg
Mitochondrial-derived 16-amino acid peptide that activates AMPK and regulates cellular energy metabolism and insulin sensitivity.
View ProtocolTeduglutide 5mg
Teduglutide is a degradation-resistant GLP-2 analog studied for mucosal growth and intestinal adaptation in short bowel syndrome models.
View ProtocolCardiogen 20mg
Synthetic short-chain tetrapeptide bioregulator studied for its potential effects on cardiomyocyte gene expression and cardiovascular integrity.
View Protocol